<DOC>
	<DOCNO>NCT01652664</DOCNO>
	<brief_summary>The purpose study evaluate intraocular pressure ( IOP ) -lowering efficacy Travoprost 0.004 % POLYQUAD ( PQ ) ophthalmic solution compare Timolol ophthalmic solution ( 0.5 % 0.25 % ) pediatric glaucoma patient .</brief_summary>
	<brief_title>Study Travoprost Ophthalmic Solution , 0.004 % Compared Timolol ( 0.5 % 0.25 % ) Pediatric Glaucoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis pediatric glaucoma ocular hypertension . Qualifying mean IOP Eligibility Visit least one eye . Written informed consent , include assent applicable , MUST obtain parent legally authorize representative prior procedure specify protocol , include screening procedure . Other protocoldefined inclusion criterion may apply . Females childbearing potential pregnant , intend become pregnant study period , breast feeding , use form birth control measure . History chronic , recurrent severe inflammatory eye disease . Ocular trauma require medical attention within past 3 month prior Screening Visit . Ocular infection ocular inflammation within past 30 day prior Screening Visit . Clinically significant progressive retinal disease . Severe ocular pathology ( include severe dry eye ) , opinion Investigator , would preclude administration topical prostaglandin analog topical betablocker . Intraocular surgery study eye within 30 day prior Screening Visit . Any abnormality prevent reliable applanation tonometry . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>